Media headlines about Marinus Pharmaceuticals (NASDAQ:MRNS) have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Marinus Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 44.8832370283034 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of brokerages recently commented on MRNS. ValuEngine lowered Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Laidlaw began coverage on Marinus Pharmaceuticals in a report on Thursday, December 14th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, BidaskClub downgraded Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 7th.
Marinus Pharmaceuticals (NASDAQ MRNS) traded down $0.37 during mid-day trading on Wednesday, hitting $5.85. The stock had a trading volume of 797,900 shares, compared to its average volume of 945,690. Marinus Pharmaceuticals has a 12-month low of $1.13 and a 12-month high of $9.87. The stock has a market cap of $236.52, a PE ratio of -6.29 and a beta of 2.09.
In other news, major shareholder Bain Capital Life Sciences Inv sold 822,547 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $8.10, for a total transaction of $6,662,630.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Christopher Michael Cashman sold 9,566 shares of the business’s stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $6.28, for a total value of $60,074.48. Following the transaction, the chief executive officer now owns 247,903 shares of the company’s stock, valued at approximately $1,556,830.84. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,107,660 shares of company stock worth $16,774,106. 6.40% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/14/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-marinus-pharmaceuticals-mrns-share-price.html.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.